Name: SCR7
Price: 220.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Scr7 is a DNA ligase IV inhibitor, initially identified as an anti-cancer agent [1]. Scr7 targets the DNA binding domain of DNA ligase IV, reducing its affinity for double strand breaks (DSBs) and inhibiting its function. Scr7 also inhibits DNA ligase III (but not DNA ligase I), albeit less efficiently. Cells were treated with doxycycline to induce Cas9 expression, with various concentrations of Scr7 for 24 h. Scr7 maintained cells capable of entering S/G2 phase, which is necessary for HDR [1]. Treatment of mice with Scr7 affects lymphocyte development, as DNA ligase IV plays a key role in the joining of coding ends during V(D)J recombination by means of C-NHEJ16. The defects in lymphocyte development upon Scr7 treatment are transient and reversible, due to the noncovalent mode of binding of Scr7. Scr7 enhanced the frequency of HDR by transiently blocking NHEJ (with the exception of DNA ligase I–dependent alt-NHEJ), resulting in precise genome editing by CRISPR-Cas9 in both cultured cells and in mice [2].
    
    [1] Srivastava M, Nambiar M, Sharma S et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21; 151 (7): 1474-87. doi: 10.1016/j.cell.2012.11.054.
    [2] Maruyama T, Dougan SK, Truttmann MC et al.Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. 2015 Mar 23. doi: 10.1038/nbt.3190. [Epub ahead of print]
- Properties
  - Alternative Name
    
    5,6-bis((E)-benzylideneamino)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one
    
    CAS Number
    
    1533426-72-0
    
    Molecular Formula
    
    C18H14N4OS
    
    Molecular Weight
    
    334.39
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥16.72 mg/mL in DMSO; ≥2.6 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Lampi Y, Van Looveren D, et al. "Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection." Sci Rep. 2019 Feb 20; 9 (1): 2389. PMID: 30787394
    2. Krüger K, Geist K, et al. "Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells." Cancer Lett. 2018 May 16; 430: 34-46. PMID:29753759
    3. Fernandez-Godino R, Bujakowska KM, Pierce EA. "Changes in extracellular matrix cause RPE cells to make basal deposits and activate the alternative complement pathway." Hum Mol Genet. 2018 Jan 1; 27 (1): 147-159. PMID:29095988
    4.Huberman LB, Coradetti ST, Glass NL. "Network of nutrient-sensing pathways and a conserved kinase cascade integrate osmolarity and carbon sensing in Neurospora crassa." Proc Natl Acad Sci U S A. 2017 Oct 10; 114 (41): E8665-E8674. PMID:28973881
    5.Hindriksen S, Bramer AJ, et al. "Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome editing in human cells." PLoS One. 2017 Jun 22; 12 (6): e0179514. PMID:28640891
    6.Lee JS, Grav LM, et al. "Accelerated homology-directed targeted integration of transgenes in Chinese hamster ovary cells via CRISPR/Cas9 and fluorescent enrichment." Biotechnol Bioeng. 2016 May 9. PMID:27159230

SCR7

SCR7

Background

We Also Recommend

BLU9931

Sephin1

SW033291